Single center experience in treating patients with t(4;14) multiple myeloma with and without planned frontline autologous stem cell transplantation

Multiple myeloma (MM) is a malignant plasma cell condition with variable long-term outcomes. Depending on the patients ’ risk factors, long-term overall survival can range from under 2 years to more than 10 years [1, 2]. One of the most important prognostic factors in this condition is disease cytogenetics, which are now commonly assessed using fluorescent in-situ hybridization (FISH) [1-3]. Amongst all of the cyt ogenetic abnormalities detected by FISH that are deemed as high-risk, translocation of the fibroblast growth factor receptor 3 (FGFR3) and multiple myeloma SET domain (MMSET) on chromosome 4 with the IgH gene on chromosome 14 is the most common, accounting for approximately 12-15% of all new cases o f MM [4].
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research